The European Patent Office intends to grant a Patent for Selection Algorithm

May 31, 2022

NextCell Pharma AB ("NextCell" or the"Company") today announces that the European Patent Office (EPO) hasissued an Intention to Grant notice relating to the patent entitled "Allogeneic Composition" (publication number EP3752598). The patent describes the method of manufacturing the drug candidate ProTrans, where the selection algorithm is key for selecting optimal cells and donors. Patent protection is valid until 2039.

The selection algorithm consists of a method for selecting cells with a suitable immunomodulatory effect that are assessed by a panel of different analyses. The algorithm makes an overall assessment of several functional analyses to identify optimal donors and cells for the manufacture of cell therapies. NextCell's accurate and advanced selection method has a scalable capability and guarantees high reproducibility and efficacy compared to other applications in cell therapy. The careful selection method results in consistently high-quality cells and hence a strong safety profile with few side effects.

"It is reassuring for NextCell that we have received positive notification from the EPO and can protect our most valuable asset," says CEO Mathias Svahn.

ProTrans is NextCell's first drug candidate based on the selection algorithm. It is an allogeneic celltherapy which means that donated cells, not the patient's own, are used. The cells are extracted from donated umbilical cord tissue and the cells are then multiplied to generate large amounts of cells.

Clinical trials intype-1 diabetes have shown promising results for ProTrans to stop the course of the disease for 1 year in adult patients, potentially longer. Ongoing trials are now evaluating efficacy in adolescents and children newly diagnosed withtype-1 diabetes. In addition, clinical trials are ongoing with patients with severe pneumonia due to COVID-19 infection, in Sweden and Canada.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 31st of May at 08.30 CET.^‍

‍

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8-735 5595
E-mail: info@nextcellpharma.com

Webpage: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser:

‍FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

‍

‍About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2019-06-19

NextCell has treated the first patient in the ProTrans-Repeat trial

NextCell Pharma AB (NextCell) announces that earlier today the first patient was treated as part of the ProTrans-Repeat trial, which is NextCell’s second clinical trial. ProTrans-Repeat is a Phase IIa clinical trial which includes patients receiving active treatment with ProTrans and who have previously been treated in the ProTrans-1 study's dose escalation phase. This means that the participants receive their second treatment with ProTrans, just over a year after the first. The goal of the ProTrans-Repeat trial is to test whether repeated treatment can increase or maintain the effect of

Read more Read more

2019-06-11

Anders Essen-Möller subscribes to his entire stakes in NextCell Pharmas right issue

The two largest owners of NextCell Pharma AB (“NextCell” or “The Company”) Anders Essen-Möller and Diamyd Medical AB, fully subscribe for their respective shares in NextCells ongoing rights issue. This means that both parties consolidate their ownership interests and that Essen-Möllers ownership in NextCell after the investments increases from approximately SEK 3.6 million to 6.0 million. Regarding the ongoing rights issue in NextCell, the principal owner Anders Essen-Möller, also the chairman of the company, has chosen to fully utilize its allotted subscription rights, which means that he

Read more Read more

2019-06-05

Selected to participate in the EIT Health Start.Smart.Global (SSG) programme.

NextCell Pharma AB (publ) ("NextCell") has been chosen as one of a select group of companies to participate in the EIT Health Start.Smart.Global (SSG) programme. The programme focusses on helping European life science SMEs successful entries into Japan and South Korea. EIT Health is a Knowledge and Innovation Community established by the European Institute for Innovation & Technology (EIT) (https://eit.europa.eu/), an independent EU body set up to promote innovation and entrepreneurship across Europe. The EIT Health Start.Smart.Global (SSG) programme, helps European life science SMEs

Read more Read more

2019-05-17

NextCell now has two parallel running clinical trials, ProTrans-1 and ProTrans-Repeat which was initiated today

NextCell Pharma AB (NextCell) announces that the initiation meeting for ProTrans-Repeat was held today at Karolinska University Hospital in Huddinge. ProTrans-Repeat is a completely independent trial and has no effect on the ProTrans-1 study. NextCell now has two ongoing clinical trials that run parallel and according to plan. ProTrans-Repeat's Principal investigator Professor Per-Ola Carlsson and the study team from Karolinska Trial Alliance, together with NextCell, went through the last practical details, which means that the new study has now been formally initiated. ProTrans-Repeat means

Read more Read more

2019-05-17

Rectification: Six out of nine patients in the first part of the phase I/II trial, ProTrans-1 have completed treatment

NextCell Pharma AB (NextCell) announces that six out of the nine patients included in the dose escalation part of ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study. Earlier this week, the last of the three patients in the so-called medium-dose-cohort visited for their 12-month follow-up, the final part of the trial, which means that all three now have completed their part of the trial. In early March, the three patients in the low-dose cohort had already completed the trial. This means that six out of nine patients in the phase I part

Read more Read more

2019-05-17

Six out of nine patients in the phase-II part of the ProTrans-1 study have completed treatment

NextCell Pharma AB (NextCell) announces that six out of the nine patients included in ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study. Earlier this week, the last of the three patients in the so-called medium-dose-cohort visited for their 12-month follow-up, the final part of the trial, which means that all three now have completed their part of the trial. In early March, the three patients in the low-dose cohort had already completed the trial. This means that six out of nine patients in the phase II part have now successfully

Read more Read more

2019-05-15

NextCell Pharma invited speaker at the World Advanced Therapies & Regenerative Medicine Congress

NextCell Pharma AB ("NextCell") and Cellaviva have been invited to attend and speak at the 14th annual World Advanced Therapies & Regenerative Medicine Congress, which is held at the Business Design Centre, London 15 - 17 May. On 16 May, CEO Dr. Mathias Svahn will be chairing the Roundtable Discussion Session regarding hospital exemption procedures. For the duration of the conference NextCell/Cellaviva delegates will be participating in workshops, attending lectures and engaging in a variety of networking activities. The World Advanced Therapies & Regenerative Medicine Congress is an

Read more Read more

2019-05-09

ProTrans-Repeat, an approved clinical trial for repeated treatment of patients with diabetes

The Medical Products Agency has granted NextCell Pharma AB ("NextCell") permission to conduct the new study, ProTrans-Repeat. The study is a continuation of ProTrans-1 where patients with type-1 diabetes who participated in the dose escalation part will be asked to participate in ProTrans-Repeat. The purpose is to investigate whether repeated treatment is safe and gives increased effect on the patient's ability to produce insulin. ProTrans-Repeat is a Phase IIa clinical trial that aims to evaluate whether repeated treatment can increase or maintain the effect of ProTrans over a longer period

Read more Read more